P3 Health Partners (PIII) to Announce Earnings on Monday

P3 Health Partners (NASDAQ:PIII – Get Free Report) is projected to issue its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($1.8950) per share and revenue of $377.80 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

P3 Health Partners (NASDAQ:PIII – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of ($4.85) by $5.17. The firm had revenue of $386.39 million for the quarter, compared to analysts’ expectations of $391.45 million.

Get P3 Health Partners alerts:

P3 Health Partners Stock Performance

NASDAQ PIII traded up $0.55 on Monday, hitting $10.38. The stock had a trading volume of 5,703 shares, compared to its average volume of 587,534. The firm has a 50-day moving average of $11.33 and a 200-day moving average of $6.07. The company has a market capitalization of $75.15 million, a price-to-earnings ratio of -0.27 and a beta of 1.63. P3 Health Partners has a 52-week low of $1.52 and a 52-week high of $16.89.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PIII shares. Wall Street Zen upgraded P3 Health Partners to a “hold” rating in a research report on Saturday, July 4th. TD Cowen reiterated a “hold” rating and set a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. Lake Street Capital reissued a “buy” rating and issued a $14.00 price target (up from $4.00) on shares of P3 Health Partners in a report on Friday, May 15th. Weiss Ratings raised shares of P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. Finally, UBS Group set a $14.00 target price on P3 Health Partners in a research note on Friday, May 15th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.00.

View Our Latest Research Report on PIII

About P3 Health Partners

(Get Free Report)

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

Recommended Stories

• Five stocks we like better than P3 Health Partners
• Large Caps Across Planes, Tech and Oil Announce Over $10 Billion in Buybacks
• A Sweet Beat and a Wearables Rally Came With Reasons to Pause
• 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
• 3 Humanoid Robot ETFs to Ride a Speculative Trend

Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.